Evidence map›Paper›PMID 28877935›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2017

Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.

Xiao Wang, Jun Yao, Jinyang Wang, Qingling Zhang, Samuel W Brady, Banu Arun, Victoria L Seewaldt, Dihua Yu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Xiao WangDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Jun YaoDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Jinyang WangDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Qingling ZhangDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Samuel W BradyDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Banu ArunDepartment of Breast Medical Oncology and Clinical Cancer Genetics Program, University of Texas MD Anderson Cancer Center, Houston, Texas.
Victoria L SeewaldtDepartment of Population Sciences, City of Hope, Duarte, California.
Dihua YuDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. dyu@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USCity of Hope · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Diversity Supplement to Combined Breast MRI/Biomarker Strategies to Identify Aggressive BiologyU01CA189283 · NCI · DUKE UNIVERSITY · PI CLINTON, STEVEN K, MIRANDA-CARBONI, GUSTAVO ADOLFO · 2015 to 2020
$4.0M
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBCR01CA112567 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, DIHUA · 2005 to 2016
$3.0M
Tension-Stat3-miR-mediated metastasisR01CA192914 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEEWALDT, VICTORIA L., WEAVER, VALERIE MARIE · 2015 to 2019
$2.9M
Inhibition of brain metastasis by blocking MAPK12 driver kinase functionsR01CA208213 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, DIHUA · 2017 to 2021
$2.4M
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast CancerR01CA184836 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, DIHUA · 2015 to 2019
$1.8M
KCNK9 Imprinting in Breast Cancer Progression and MetastasisR01CA155664 · NCI · DUKE UNIVERSITY · PI SEEWALDT, VICTORIA L. · 2011 to 2015
$1.8M
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical TestingR01CA158668 · NCI · DUKE UNIVERSITY · PI SEEWALDT, VICTORIA L. · 2012 to 2016
$1.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA112567NCI NIH HHS R01 CA155664NCI NIH HHS R01 CA158668NCI NIH HHS R01 CA184836NCI NIH HHS R01 CA192914NCI NIH HHS R01 CA208213
6 · The paper itself

Abstract

The prevention of estrogen receptor-negative (ER-) breast cancer remains a major challenge in the cancer prevention field, although antiestrogen and aromatase inhibitors have shown adequate efficacy in preventing estrogen receptor-positive (ER

Indexed as

AnimalsAntineoplastic AgentsBiopsy, Fine-NeedleBreastBreast NeoplasmsCell Line, TumorCell ProliferationCyclin B1Erb-b2 Receptor Tyrosine KinasesFemaleG1 Phase Cell Cycle CheckpointsGene Expression ProfilingHumansIndazolesMammary Neoplasms, ExperimentalMice2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineAntineoplastic AgentsCCNB1 protein, humanCyclin B1ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIndazolesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktReceptors, EstrogenRibosomal Protein S6 Kinases, 70-kDaSulfonamides

Identifiers

PMID28877935
PMCPMC5668174
OpenAlexW2753138769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.